Longevity
Vilon
Khavinson bioregulator
Khavinson short peptide bioregulator
This Vilon entry draws on 3 cited sources published 2002 to 2021. The evidence available is graded Russian Research on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Khavinson short peptide bioregulator
- Drug class
- Longevity
- Structure
- Dipeptide Lys-Glu
- Route
- Oral / SC
- Half-life
- Short (minutes)
- Evidence tier
- Russian Research
- Availability
- Research
- Research depth
- 64 indexed citations →
Mechanism of action
DNA binding; gene expression modulation in immune tissues
Reported areas of research
Thymus support; immune aging; gene expression modulation
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
Oral capsule 1-2x daily
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Limited Western evidence
Compared with
Vilon has published head-to-head comparisons with 16 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for Vilon in research literature?
Published peptide research reports the following dosing approach for Vilon: Oral capsule 1-2x daily. This is a research reference, not a clinical recommendation.
How is Vilon administered in research?
Vilon is administered via the following routes in published studies: Oral / SC.
What is the reported half-life of Vilon?
No measured half-life for Vilon is reported in the literature catalogued here. The catalog describes it as: Short (minutes).
Is Vilon FDA-approved?
No. Vilon is not an FDA-approved drug. PeptideHelper.org catalog status: Research.
What level of evidence supports Vilon?
The current evidence base for Vilon is best characterised as: Russian Research. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Vilon?
Known concerns reported in the literature for Vilon include: Limited Western evidence. Always consult a qualified clinician before any human use.
Is there anyone who should not use Vilon?
No formal contraindications are established for Vilon, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Limited Western evidence. Always consult a qualified clinician before any human use.
How does Vilon work?
The mechanism of action reported for Vilon in the literature: DNA binding; gene expression modulation in immune tissues.
What is Vilon studied for?
Vilon has been studied in the published literature for: Thymus support; immune aging; gene expression modulation. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Vilon?
Vilon is classified as: Khavinson short peptide bioregulator. Also known as: Khavinson bioregulator.
Drug class
- Khavinson peptides, see all peptides tagged Khavinson.
Research focus area
All peptides studied for Longevity, ranked by evidence tier and regulatory status.
Primary sources
- Khavinson VKh et al. Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway (Vilon, Lys-Glu). Bull Exp Biol Med 2002. PMID 12420072
- Khavinson VK et al. Peptide regulation of gene expression — a systematic review. Molecules 2021. PMID 34834147
- Note: Primary literature on this peptide is published largely in Russian gerontology journals (Adv Gerontol, Bull Eksp Biol Med). English-indexed sources are limited to comprehensive Khavinson-laboratory reviews; entry confidence is correspondingly lower.
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…